



# Vimizim in Jordan

*The JFDA named-patient coordination pathway — indicative 2026*

RARE DISEASE · MPS IVA (MORQUIO A)

## The clinical situation

Vimizim (elosulfase alfa) is an FDA-approved recombinant N-acetylgalactosamine-6-sulfatase enzyme replacement therapy for Morquio A syndrome (MPS IVA), dosed 2 mg/kg IV weekly. Manufactured by BioMarin. Weight-based dosing, cold-chain shipment, and skeletal / respiratory monitoring are required. Infusion-related reactions are managed with premedication and rate adjustment.

### The pathway, 5 steps

- 1 Consultation & diagnostic confirmation.** Treating metabolic specialist confirms GALNS deficiency and Morquio A phenotype; weight-based weekly dose calculated.
- 2 Infusion centre confirmed.** A Jordanian tertiary metabolic centre (Amman) commits to weekly infusion slots and skeletal-pulmonary monitoring.
- 3 JFDA named-patient application.** Clinical rationale, enzyme assay, dose calculation, and product details are filed with JFDA for import clearance.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked to weekly schedule.
- 5 Infusion & monitoring.** Weekly IV infusions under specialist supervision; endurance, pulmonary, and skeletal monitoring per label.

### Indicative economics

**Reference US cash-pay range:** USD 30,000–40,000 per month (weight-based) drug-only. Cold-chain logistics, JFDA documentation, infusion-centre fees, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-infusion timing

**7–14 days** from a complete JFDA application to first-infusion delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** JFDA named-patient package with enzyme-assay confirmation. **Logistics.** Cold-chain, temperature-monitored shipment coordination on a weekly schedule. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Vimizim × Jordan first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/vimizim-jordan.html](https://reservemed.com/access-guides/vimizim-jordan.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team